Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Listed as NCT03462641, this PHASE1/PHASE2 trial focuses on Parkinson Disease and remains completed. Sponsored by National Institute of Neurological Disorders and Stroke (NINDS), it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Completed PHASE1_PHASE2
-
Sep 2021 — Jul 2022 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2019 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2018 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .